CJMMIC Partner Companies Visit Intellective Bio-Newsroom

Recently, a delegation of partner companies from the China-Japan Medicine and Materials Innovation Center (CJMMIC), led by Dr. Xu Ping, Chairman of Huilly Pharma, visited Intellective Bio’s Changshu site for an exchange session. The delegation included representatives from renowned enterprises such as Sinovent, Abogen Life Sciences Limited, Transcenta Holding, Etta Biotech, Langrui Biomedicine, Phrontline Biopharma and Senhui Microsphere Tech.

In the morning, the delegation visited Xingfu Temple in Changshu. Amid the warm spring sunshine, they climbed to a vantage point to enjoy the scenery and experience the tranquility and serenity of this ancient Jiangnan temple.

In the afternoon, the delegation arrived at Intellective Bio, where they were warmly welcomed by the company's senior leadership. Mr. Alex Li, Founder and CEO of Intellective Bio, provided a detailed introduction to the company's development history, core business, technological advantages and future strategic plans.

Mr. Li emphasised that Intellective Bio is dedicated to providing high-quality, efficient CDMO services for global biopharmaceutical companies. He also highlighted the company's active efforts to expand into cutting-edge technological fields, aiming to become a key player in the global biopharmaceutical industry.

During the subsequent discussion session, representatives from the partner companies engaged in an in-depth exchange with Mr. Li on various topics, including biopharmaceutical industry trends, technological innovation, and market opportunities. Regarding industry trends, participants identified three major opportunities: the evolution of antibody drugs toward complex formats such as bispecific and trispecific antibodies, and accelerated breakthroughs in cell and gene therapy technologies. In terms of technological innovation, the industry is advancing through a dual-driven model of "AI + Biopharma," leveraging self-developed algorithms to improve target prediction accuracy and shorten molecular design cycles. Regarding market opportunities, companies emphasised the importance of continued innovation and addressing unmet clinical needs, noting that international expansion and securing sustainable growth remain critical trends for domestic enterprises.

Drawing on his extensive experience, Mr. Li addressed the delegates' questions and shared his insights on the future development of the industry.

This visit provided a valuable platform for exchange and learning among CJMMIC partner companies and laid a solid foundation for potential future collaborations in the biopharmaceutical field. Moving forward, the center will continue to leverage its platform advantages to foster communication and cooperation among member enterprises, jointly contributing to the high-quality development of China's biopharmaceutical industry.